



Covid-19: Medicines Criticality Group

Department of Health, Miesian Plaza,

Actions – Tuesday, 7th April 2020

No	Action Detail	Owner	By When	Latest Update	Status
1	Monitoring of medicines used in Irish hospitals that may be used to treat Covid 19, to treat secondary infections and as supportive treatments	AHDMP & PCRS	Ongoing	AHDMP actively managing agents where required, follow up ongoing. PCRS reviewing antimicrobials and respiratory products. Overall supply looks ok- follow-up with MAH required regarding azithromycin supplies. Wholesalers still finalizing March figures for supply AHDMP and have committed to twice weekly follow up	Open
2	MAHs to be contacted re availability of investigational therapeutics	AHDMP & PCRS	Ongoing		Open
3	HPRA to provide update on status of questionnaire to MAHs	HPRA	Ongoing	No significant issues currently. On the whole, general supply looks ok	Open
4	Securing ICU EMP supplies,	AHDMP	31/03	NMBAs to remain at amber, over the coming weeks, barring a sharp increase in ICU occupancy. Prescribing behavior circular issued, but further change will be critical AHDMP to send Department of Health the correspondence issuing in relation to neuromuscular blockers. Department of Health to determine any other routes for encouraging review and change of behavior to use full therapeutic range of products available AHDMP to inform HPRA of current information re. existing stock. Mechanism for flagging potential local shortages to be considered by AHDMP (no shortages at this point)	Open



				HPRA to provide support to AHDMP on quality of supplies sources from third countries [RISK MITIGATION OUTLINED BELOW]	
Neuromuscular blocking agents – increased global demand and limited availability					
Risk Mitigation Strategy			Action Owner		Risk Status
Support prescribing of the therapeutic class, not just one moiety within the class			Critical Care Programme and Prescribers		Medium
Centrally engage with MAH holders and suppliers of unlicensed drugs to ensure additional stocks are secured			AHDMP		Medium
Watching brief by HPRA Medicines Shortages unit and AHDMP to identify early disruptions to supply			AHDMP/HPRA		Medium
Escalation of European wide supply chain vulnerability to EU Commission			DOH		Medium
5	HSE Modelling data to be shared with group when available	DoH	Ongoing	Further engagement with modelling group to be scheduled	Open
6	PCRS to update Group on mechanism to limit <i>de novo</i> patients on hydroxychloroquine for antiviral purposes	PCRS	Ongoing	PCRS reviewing incoming claims against clinical guidance.	Open
7	Paracetamol supplies	All		No issues beyond short term suppository supply delays. To remain under review, in case further action is required to cover OTC supply.	Open
8	Parallel exporting	HPRA		Wholesalers have confirmed not supplying commercial accounts. Joint communications to issue from PSI and HPRA reminding RPB WDA holders of their obligations. Exporters following normal rules-continue to be monitored. HPRA following up with a small number of WDA holders that operate by exporting from the Irish market	Open
9	Immunocompromised patients	HSE National Quality Improvement		Communication awaiting final sign off. Expected to go live today. PCRS to be looped in for primary care dissemination	Open
10	Group to review impact of comms as regards the perceived pull on supply	DoH / HPRA	Ongoing	Department of Health to reconvene comms group to update messaging.	Open



	chains and changes in messaging				
11	If hospital treatments move into community, DoH to be informed for eligibility considerations	AHDMP & PCRS	Ongoing		Open
12	Establishment of a stakeholder forum, to operate outside Subgroup meetings	Department of Health/ PSI	31/03	Paused while parallel activity is progressed	On hold
13	MAH to be asked to issue communication to reassure patient groups re HCQ supplies	AHDMP	07/04	AHDMP to follow up with MAH	Open
14	supplies of HCQ	AHDMP		AHDMP to check with relevant MAH on HCQ stocks and supply chains	Open
15	Export prohibitions	HPRA/ DOH		HPRA to continue developing case studies where UK prohibition has impacted on supply Department of Health to engage with DOH colleagues to enable approach to UK Department of Health and Social Care to be made	Open